Momecort

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Momecort

Overview: What is Momecort?

Property Description
Active ingredient Mometasone Furoate
Common Forms Cream, Ointment, Nasal Spray (Rx)
Pharmacological Class Synthetic Glucocorticoid (Corticosteroid)
Origin Synthetic (Man-made)
Primary Therapeutic Goal Symptomatic management of inflammation and allergic responses

Momecort is a brand name for a prescription medication containing the active ingredient mometasone furoate, which is classified as a synthetic glucocorticoid. This medicine is often prescribed by doctors for conditions that involve excessive inflammation and itching, such as various forms of dermatitis and psoriasis. It is clinically recognized for providing potent, localized anti-inflammatory relief.

The medication is available in several forms (cream, ointment, or nasal spray), with the different preparations allowing for targeted treatment of specific conditions. This range of formulations ensures the medication can be applied directly to the affected area for localized relief.


Momecort’s Composition and Classification

The core compound in Momecort is mometasone furoate, its International Nonproprietary Name (INN), which places it firmly within the pharmacological class of corticosteroids. It is an engineered, synthetic molecule designed to be a highly effective anti-inflammatory agent.

Pharmacological studies have confirmed that mometasone furoate has a particularly high binding affinity for glucocorticoid receptors. This potent, targeted binding helps explain its efficacy in reducing swelling, redness, and itching associated with certain skin and nasal conditions.


What is Momecort Used For?

The general therapeutic purpose of Momecort is to manage and control symptoms arising from various inflammatory and allergic disorders. Unlike routine moisturizers, it is a potent agent reserved for conditions that require a strong localized response to suppress the immune system's overreaction.

By providing strong anti-inflammatory support, Momecort helps stabilize the affected area, offering significant symptom relief and supporting the body's natural healing process in conditions where excessive inflammation is a key problem.

Regulatory References

  1. Mometasone Furoate Indications (NIH DailyMed)

What side effects are possible with Momecort?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Mometasone Furoate (Momecort) as officially documented in government regulatory labeling. The safety profile is structured to account for both local effects at the application site and potential systemic absorption typical of corticosteroids.


Official Adverse Reaction Groupings

The following is a summary of adverse effects classified by frequency and system involvement, based on regulatory reports for the various Momecort formulations:

  • Common Reactions (Reported for Nasal Spray): Headache, Pharyngitis (sore throat), and Epistaxis (nosebleeds).
  • Local Skin/Application Site Reactions (Topical): Burning, Pruritus (itching), Stinging, and Skin atrophy (thinning), which are typically associated with topical corticosteroid use.

Serious Adverse Reactions and Safety Constraints

The most significant, although less common, safety concerns are related to systemic corticosteroid effects. Prolonged or extensive use increases the risk of serious adverse reactions, which include:

  • Endocrine Effects: Manifestations of Hypercorticism (such as Cushing's syndrome) and HPA axis suppression (adrenal suppression) due to the systemic absorption of the glucocorticoid.
  • Ocular Effects: The development of Cataracts or Glaucoma, documented particularly with long-term exposure.
  • Pediatric Safety: Pediatric patients are officially noted to be more susceptible to systemic toxicity, and growth suppression is a documented risk with prolonged use of corticosteroids in this population.
  • Topical Restriction: The official label prohibits use on wounds or ulcerated skin, or in patients with known hypersensitivity to the medicine.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents state that an overdose of Momecort is primarily related to the consequences of prolonged use or use at higher than recommended dosages. Acute, single-event toxicity is generally deemed unlikely due to the drug’s low systemic bioavailability.

Element Official Regulatory Statement
Documented overdose presentations Clinical manifestations of systemic glucocorticoid excess, including Hypercorticism and Cushingoid features.
Physiological systems affected Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, potentially resulting in secondary adrenal insufficiency.
Population-specific overdose notes Pediatric patients may exhibit greater susceptibility; growth velocity requires routine monitoring.

Official Overdose Statements:

  • Chronic overdose may lead to HPA axis suppression, and the required management procedure is symptomatic and supportive treatment.
  • Urgent medical attention is required if signs of a severe allergic reaction (e.g., swelling, wheezing) or signs of adrenal insufficiency become clinically significant.
  • If a patient has evidence of HPA axis suppression due to high-dose use, additional systemic corticosteroid cover should be considered during periods of stress or elective surgery, a procedural instruction requiring urgent medical consultation.

Connection to the overall overdose profile: Regulatory documents define the Momecort overdose profile by the risk of HPA axis suppression resulting from prolonged systemic absorption. This classification mandates that patients must be monitored for adrenal function, and urgent medical help is required when consequences such as a severe allergic reaction or clinically significant adrenal insufficiency manifest.

Therapeutic Uses of Momecort

What Momecort Treats: Main Uses and Benefits

Momecort, containing Mometasone Furoate, is applied across domains where additional symptomatic support is needed to address conditions presenting with heightened symptoms. The medication is commonly used to help with eczema (atopic dermatitis), psoriasis, seasonal and perennial allergic rhinitis, and nasal polyps. It is relevant in contexts marked by increased discomfort due to inflammatory or irritative states.

In chronic skin conditions, Momecort helps address symptom clusters that may become intense or disruptive, such as pronounced redness, localized swelling, and persistent itching. In nasal applications, it is used when groups of symptoms, including congestion, sneezing, and runny nose, interfere with daily comfort. The overall therapeutic benefit provides support that helps ease the overall symptom burden, particularly when symptoms intensify.

“This medication supports the patient during difficult episodes, easing distress and assisting with maintaining a sense of stability.”


Quick Fact: Relief for Inflammatory Symptoms

Quick Fact: Relief for Inflammatory Symptoms Momecort is applied in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief that may assist with easing the impact of dermal and nasal inflammation on routine activities.

Regulatory References

  1. NIH MedlinePlus overview of Mometasone Topical

Eligibility and Restrictions for Use

The eligibility for using Momecort (mometasone furoate) is strictly governed by regulatory labeling and varies significantly based on the specific product formulation (topical vs. nasal spray) and the patient's age.


Eligibility Scope

Classification Population Rule According to Labeling
Allowed Populations Generally includes adults and adolescents (12 years and older). Topical cream/ointment use is also permitted in children 2 years of age and older [FDA Label: ELOCON].
Use Not Established Use in children under 2 years of age is not recommended for any formulation, as safety and efficacy have not been formally established in this age group [DailyMed: Cream].
Contraindicated Use is prohibited in patients with a documented hypersensitivity to any component of the formulation [FDA Label: NASONEX].
Local Contraindications Topical forms are contraindicated for use on facial rosacea, acne vulgaris, perioral dermatitis, or in the presence of untreated bacterial, fungal, or viral skin infections [SmPC: Topical]. Nasal spray is contraindicated with recent nasal surgery or unhealed ulcers [FDA Label: NASONEX].
Conditional Use Use during pregnancy and lactation is restricted; it is permitted only if the potential benefit justifies the potential risk [SmPC: Nasal]. Caution is also advised for patients with a history of tuberculosis or certain existing ocular conditions (e.g., glaucoma) [FDA Label: NASONEX].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The official interaction profile for Momecort (Mometasone Furoate) is structured around two key areas: pharmacokinetic interactions affecting its metabolism and clearance, and pharmacodynamic interactions related to additive steroid effects.

Category
Medicinal product categories with documented interactions: Strong Cytochrome P450 3A4 (CYP3A4) Inhibitors (pharmacokinetic interaction) and Other Corticosteroids (pharmacodynamic interaction).
Specific interacting medicines (if explicitly listed): Cobicistat-containing products and Ritonavir are documented as strong CYP3A4 inhibitors.
Mechanistic basis of interactions (as stated in regulatory sources): Co-administered CYP3A4 inhibitors slow the medicine’s metabolism, leading to reduced clearance and increased systemic exposure.
Timing-based interaction rules (if applicable): None formally documented as a mandatory time separation rule.
Population-specific interaction notes (if applicable): Hepatic Impairment (liver disease) may increase Momecort's effects due to potential slower removal from the body.
Interaction-related restrictions: Co-treatment with strong CYP3A4 inhibitors should be avoided unless the benefit is determined to outweigh the increased risk of systemic side-effects.

Resulting Interaction Structure

The co-administration of Momecort with strong CYP3A4 inhibitors is expected to significantly increase the systemic exposure to the medicine, which raises the risk of systemic corticosteroid effects. Consequently, regulatory documents formally restrict the use of these combinations. Additionally, co-administration with other corticosteroid products carries an additive risk of systemic effects. The official profile further notes that patients with hepatic impairment require caution due to the potential for increased drug effects.

Mechanism of Action

How Momecort Works at the Cellular Level

Momecort acts as an agonist for the intracellular Glucocorticoid Receptor (GR), a transcription factor found in nearly all cells. The activated drug-receptor complex translocates into the cell nucleus, where it directly modulates gene transcription. This process shifts the cell’s function by suppressing genes that produce pro-inflammatory mediators, such as NF-kappa B-regulated cytokines, and activating genes that produce anti-inflammatory proteins, resulting in a suppression of the localized immune response.

Suppression of Inflammatory Signal Cascades

The mechanism involves the suppression of the Arachidonic Acid Pathway. By upregulating Lipocortin-1 (Annexin A1), the drug indirectly inhibits the enzyme Phospholipase A2 (PLA₂), which is essential for releasing arachidonic acid. This interference halts the production of all major classes of downstream pro-inflammatory mediators, including prostaglandins and leukotrienes. This inhibition leads to the physiological effects of vasoconstriction and a reduction in localized tissue edema.

Dosage and Administration Information

Official Administration Guidelines for Momecort

Momecort (Mometasone Furoate) is administered according to the specific formulation prescribed, which dictates the route and corresponding dosage pattern. The medication is used either topically (cream, ointment, or lotion 0.1%) for dermal conditions or intranasally (metered spray 50 mu g/actuation or specialized implant) for nasal conditions.


Standard Dosing and Frequency

Topical 0.1% preparations are applied as a thin film once daily to the affected skin areas. For adults and adolescents (12 years and older) treating allergic rhinitis with the nasal spray, the standard regimen is two sprays (100 mu g) in each nostril once daily. When treating nasal polyps in adults, the prescribed dose may increase to be administered twice daily, resulting in a maximum total daily dose of 400 mu g.


Time-Bound Use and Special Instructions

Use of topical formulations should be discontinued when control is achieved. Long-term continuous application is generally avoided, and treatment should be reassessed if no improvement is observed within two weeks. For intranasal spray use, the device must be shaken well and primed prior to initial use or if left unused for a period exceeding one week. Topical preparations must not be applied with occlusive dressings (e.g., bandages or diapers) unless otherwise directed. For seasonal allergy prophylaxis, use may be initiated two to four weeks prior to the anticipated start of the pollen season.


Population-Specific Rules

Topical preparations are not recommended for use in children under 2 years of age. Pediatric dosing for nasal spray in children aged 2–11 years for rhinitis is reduced to one spray (50 mu g) in each nostril once daily, totaling 100 mu g per day.

Recent Clinical Evidence

Momecort: Recent Clinical Evidence

This section outlines the landscape of clinical research conducted for Momecort (mometasone furoate), focusing on the types of studies performed, the patient groups examined, and the areas where the research remains limited. It does not provide medical advice or instructions on how to use the medicine.


Evidence for Use in Seasonal and Perennial Allergic Rhinitis (Nasal Spray)

Research has studied the Momecort nasal spray formulation primarily through short-term Randomized Controlled Trials (RCTs) and systematic reviews in adults and children (aged six years and older). Studies examined outcomes related to physical discomfort, such as Total Nasal Symptom Scores (TNSS) and patient-reported symptoms like congestion and itching. The initial research focused on defined time intervals, typically 2 to 16 weeks. Comparative evidence for direct head-to-head research against all alternative nasal medicines is limited.


Evidence for Use in Corticosteroid-Responsive Skin Conditions (Cream/Ointment)

Topical forms (cream and ointment) were evaluated in Controlled Clinical Trials for conditions characterized by episodic inflammation like eczema and psoriasis. Research explored outcomes linked to inflammatory or irritative states, tracking physical signs (redness, scaling) and patient-reported discomfort (itching). Research findings have not been established for the pediatric population below two years of age.


Evidence for Use in Nasal Polyps (Nasal Spray)

Momecort nasal spray was studied for the management of nasal polyps using intermediate-term Controlled Trials in adults. These studies monitored objective measures like polyp size (via endoscopic scoring) alongside outcomes reflecting daily functioning, such as nasal obstruction and smell. Research also explored the use of the medicine post-surgery. Subgroup findings are uncertain for adolescents, and long-term recurrence data is limited.


Documented Evidence Gaps and Uncertainties

Clinical studies for most indications involve limited follow-up durations, meaning long-term effects are not fully established regarding sustained symptom status. Data for certain groups, most notably children under two years old, remain insufficient. While the research describes how symptoms evolved in studied groups, studies help show what has been observed so far, but research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Momecort (FAQ)

Q: How quickly does Momecort start working after the first use?

A: According to official product information, for the nasal spray formulation, some people may start to feel initial relief within 12 hours of the first dose. However, the full effectiveness is generally observed after several days of regular use. Achieving the full benefit is generally supported by consistent use as directed by a healthcare provider.

Q: Is there a generic version of Momecort available?

A: Mometasone Furoate is the active ingredient contained in Momecort. Official prescription information indicates that Mometasone Furoate is available generically for certain formulations, including the nasal spray.

Q: What happens if I stop using Momecort suddenly?

A: Regulatory warnings indicate that suddenly stopping long-term or extensive use of this medicine may increase the risk of adrenal suppression. This condition, also known as HPA axis suppression, involves the body's natural production of glucocorticosteroids becoming temporarily insufficient. Regulatory warnings emphasize the importance of medical supervision when considering discontinuing the medication.

Q: Does Momecort cause weight gain?

A: Weight gain is not listed as a common side effect of Momecort. However, official safety information notes that prolonged or extensive use, which leads to significant systemic absorption, may risk manifestations of hypercorticism, also known as Cushing’s syndrome. These systemic effects, if they occur, can be associated with metabolic changes.

Q: Does Momecort affect sleep?

A: Official adverse reaction reports indicate that certain central nervous system (CNS) effects, such as somnolence (sleepiness) or impaired mental alertness, have been observed. This is particularly noted when the Mometasone ingredient is used in combination with other active medicines.

Q: What does the term 'corticosteroid' mean in relation to Momecort?

A: Momecort belongs to the pharmacological class known as corticosteroids. This means it functions as a potent anti-inflammatory and anti-allergic agent. Its function is to provide potent anti-inflammatory and anti-allergic support to manage symptoms like swelling and redness.

Q: Is Momecort commonly available over the counter?

A: The active ingredient, Mometasone Furoate, is available in different formulations. Official product information indicates that the nasal spray formulation is available both by prescription and over-the-counter (OTC) for the management of allergic symptoms.

Q: Can I drink alcohol while using Momecort?

A: Regulatory documents for a combination product containing Mometasone advise avoiding concurrent use with alcohol. This caution is issued because combining the substances may lead to additional reductions in alertness and impairment of mental performance.

Q: Does Momecort interact with common pain relievers like ibuprofen?

A: Specific drug interaction studies between Momecort alone and non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are generally not reported. General warnings exist for the co-use of systemic corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.

Q: What happens if I miss a use of Momecort?

A: Official patient instructions describe a procedure for missed doses: if a dose is missed, it is generally taken as soon as remembered, but if it is nearly time for the next dose, the missed one is skipped. Instructions emphasize not taking a double dose to compensate for the missed one.

Q: Is Momecort a maintenance or a rescue medicine?

A: Momecort is generally regarded as a maintenance treatment in its official descriptions. This classification is supported by its recommendation for daily use and its indication for prophylaxis, which is the prevention of symptoms, often prior to the start of the pollen season.

Q: Can Momecort be used along with other topical treatments?

A: Official documentation addresses the use of Momecort alongside other topical products when skin infections are a concern. It indicates that if concomitant skin infections are present, an appropriate antifungal or antibacterial agent should be used along with the Momecort topical formulation.

Q: Is Momecort known to affect blood sugar levels?

A: Official warnings state that systemic absorption, especially with high-dose or prolonged use, can potentially produce manifestations of hyperglycemia, which is an elevated level of blood sugar. This effect is a documented risk for corticosteroids, and official information indicates that caution is advised for patients with existing blood sugar conditions.

Q: What does 'contraindication' mean for Momecort?

A: A contraindication is a regulatory term for a specific condition or circumstance where the use of Momecort is formally prohibited. This prohibition is in place because the potential risks associated with the medicine are judged to outweigh any possible benefit for patients with that particular condition.

Q: Is Momecort suitable for use in elderly patients?

A: According to clinical data gathered during trials, no overall differences in safety or effectiveness have been shown between geriatric patients and younger adult patients. Regulatory guidelines do not typically specify dosage adjustments based solely on age for this population.

Q: How long does the effect of one dose of Momecort last?

A: The administration guidelines for Momecort typically prescribe it for once-daily dosing for many indications. This dosing frequency suggests that the therapeutic effects of the medicine are intended to last for approximately 24 hours.

Q: Do studies suggest Momecort is effective for chronic use?

A: Clinical studies support the use of the Mometasone Furoate nasal spray formulation for the treatment of chronic rhinosinusitis with nasal polyps in adults. This is one example of a condition requiring chronic management that is addressed by the official indications for the medicine.

Q: Is Momecort known to interact with herbal supplements?

A: Regulatory patient information often cautions that there may not be enough formal safety data available regarding the co-use of Momecort with various herbal remedies, vitamins, or dietary supplements. Official information emphasizes the importance of sharing a complete list of all products, including supplements, with a healthcare provider.

Q: What should I do if I experience an unusual side effect from Momecort?

A: Official patient safety information indicates that if symptoms listed as serious side effects occur (e.g., wheezing, difficulty breathing, vision problems), the medication is discontinued, and emergency medical attention is sought.

Q: Can Momecort be used long-term?

A: Official safety warnings note that prolonged or long-term use of Momecort is associated with an increased risk of systemic side effects, including the potential development of cataracts or glaucoma. Therefore, long-term use requires periodic monitoring by a healthcare professional.

Q: Is Momecort absorbed into the bloodstream?

A: Yes, regulatory documents confirm that Momecort can be absorbed systemically, meaning it can enter the bloodstream. This systemic absorption may lead to potential effects on the body's endocrine system, which is why precautions are taken regarding high-dose and long-term use.

How should Momecort be stored and disposed of?

Storage & Disposal Scope

Labeled Storage Temperature Requirements Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with certain excursions permitted for topical forms.
Handling and Prohibitions Do not freeze Mometasone Furoate suspension/spray formulations. Avoid excessive heat when storing the topical cream or ointment.
Stability After Opening (Nasal Spray) The nasal spray must be discarded 75 days or 2 months after the date of first use, regardless of any remaining medicine.
Packaging Requirements The nasal spray container should be kept tightly closed when not in use.
Child-Protection Storage Requirements All Momecort formulations must be stored out of the sight and reach of children for safety.
Disposal Instructions Dispose of unused or expired product according to local regulatory requirements. Medicines should generally not be disposed of via wastewater or household waste unless specified by official guidance.

Connection to the overall storage/disposal profile: Regulatory documents mandate precise temperature control and prohibit freezing to maintain product stability. Labeled constraints specify the in-use shelf-life for the nasal spray after opening. Final disposal must adhere to local environmental rules, preventing unauthorized household waste disposal in many regions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Momecort found in:

A-Z Index: